On Tuesday, Vir Biotechnology Inc (NASDAQ: VIR) was -8.46% drop from the session before settling in for the closing price of $6.15. A 52-week range for VIR has been $4.95 – $14.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 423.44% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 12.21%. With a float of $88.05 million, this company’s outstanding shares have now reached $136.96 million.
In an organization with 408 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 86.84%, operating margin of -707.97%, and the pretax margin is -715.51%.
Vir Biotechnology Inc (VIR) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vir Biotechnology Inc stocks. The insider ownership of Vir Biotechnology Inc is 36.22%, while institutional ownership is 51.06%. The most recent insider transaction that took place on Apr 03 ’25, was worth 474,239. In this transaction Chief Executive Officer of this company sold 79,712 shares at a rate of $5.95, taking the stock ownership to the 769,505 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Officer and Director proposed sale 79,712 for $5.95, making the entire transaction worth $474,239.
Vir Biotechnology Inc (VIR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 12.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.12% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
You can see what Vir Biotechnology Inc (VIR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.83, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Vir Biotechnology Inc (VIR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.14 million. That was inferior than the volume of 1.82 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.30%. Additionally, its Average True Range was 0.39.
During the past 100 days, Vir Biotechnology Inc’s (VIR) raw stochastic average was set at 7.16%, which indicates a significant decrease from 31.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.73% in the past 14 days, which was lower than the 96.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.64, while its 200-day Moving Average is $8.10. However, in the short run, Vir Biotechnology Inc’s stock first resistance to watch stands at $5.91. Second resistance stands at $6.18. The third major resistance level sits at $6.33. If the price goes on to break the first support level at $5.49, it is likely to go to the next support level at $5.34. The third support level lies at $5.07 if the price breaches the second support level.
Vir Biotechnology Inc (NASDAQ: VIR) Key Stats
There are 138,064K outstanding shares of the company, which has a market capitalization of 777.30 million. As of now, sales total 74,210 K while income totals -521,960 K. Its latest quarter income was 12,370 K while its last quarter net income were -104,590 K.
